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Abstract
Vasculitis is rare in the context of testicular lesions but, when found, can be classified as a single organ vasculitis or part of a
multi-organ inflammatory process. In the context of a patient with a pre-existing autoimmune disorder, this finding might
cause diagnostic confusion and preferentially bias a physician towards attributing the condition to the known diagnosis or
its treatment. This diagnostic bias can interfere with patient care and lead to over caution, resulting in a worse outcome for
the patient involved. We describe such a patient with rheumatoid arthritis on biologic therapy.
INTRODUCTION
Single organ vasculitis (SOV) in the context of a pre-existing
autoimmune disorder can cause diagnostic confusion, especially
when a patient is immunosuppressed.Diagnostic bias can ensue
with patients being treated more cautiously than necessary
at the potential expense of their health. We report a case of
testicular vasculitis in a patient with rheumatoid arthritis (RA)
on etanercept; both of which are known to cause systemic
vasculitis.
CASE
A 66-year-old man developed painless right testicular swelling.
He had a history of RA, Parkinson’s disease and depression,
for which he was taking etanercept, carbidopa levodopa and
mirtazapine.
Examination identified a mass in the right testicle; abdomi-
nal examinationwas normal. Full blood count and liver and renal
functions were normal. C-reactive protein was <1 mg/l; ery-
throcyte sedimentation rate had been chronically above normal
with no specific cause identified. Alpha-fetoprotein and human
chorionic gonadotropin were both normal.
Ultrasound scanning showed a normal left testis but a focal
hypoechoic mass-like lesion in the right testis (Fig. 1) with sev-
eral small nodular foci which were isoechoic to background
testis. Appearances were concerning for testicular cancer. He
was seen by a urologist 2 weeks later and had a normal com-
puted tomography of the thorax, abdomen and pelvis. Within
3 weeks of the ultrasound, he had a radical orchidectomy in
accordance with European urology guidelines [1] as a malignant
tumour was suspected.
On slicing, the testis contained an ill-defined mid-zonal red-
dish/brown focus (Fig. 2).Histopathological examination showed
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Figure 1:Two representative longitudinal greyscale ultrasound views of the right testis.A relativelywell-definedhypoechoicmass-like lesion is demonstrated containing
nodular foci which are isoechoic to normal background testicle (white arrowheads). Colour Doppler (not shown) demonstrated patchy vascularity within the lesion
which was similar to that of background testicle.
Figure 2: The cut surface of the fixed testis showing an oval focus of disease left
of centre. The parenchyma surrounding the lesion is normal.
focal diffuse lymphocytic permeation of the parenchyma with
aspermatogenic seminiferous tubules, most of which contained
Sertoli cells and some spermatogonia. There was focal lympho-
cytic permeation of seminiferous tubules. Small- and medium-
sized arteries in the lesion showed various vasculitic changes,
including fibrocellular intimal thickening (Fig. 3), focal mild
permeation of the intima by lymphocytes, dense adventitial
lymphoid cell infiltration, focal transmural chronic inflamma-
tion, and focal fibrinoid necrosis with neutrophils (Fig. 4). No
granulomata were present. Some veins contained organising
thrombus, with mural inflammatory changes.
Many of the lymphocytes, including those surrounding and
infiltrating vessel walls, were T-cells (CD3+, CD5+). The intersti-
tial infiltrate also contained small numbers of mature-looking
B-cells (CD20+, CD10-), a few of which permeated arterial walls.
Molecular genetics tests confirmed that both sets of lympho-
cytes were polyclonal (reactive).
The changes indicated a form of non-granulomatous
vasculitis affecting medium-sized vessels with associated
localised chronic orchitis. The differential diagnoses included
Figure 3: A small testicular artery (top) showsmarked fibrocellular intimal thick-
ening and luminal narrowing with focal permeation of the wall by lymphocytes.
The accompanying vein (bottom) shows more extensive permeation of its wall
by lymphocytes. H&E; ×10 objective.
Figure 4: A small testicular artery shows a small focus of fibrinoid necrosis and
neutrophil permeation at a branch point. H&E; ×20 objective.
antineutrophil cytoplasmic antibody (ANCA)-associated vasculi-
tis (AAV), polyarteritis nodosa (PAN), SOV, rheumatoid vasculitis
or drug-induced vasculitis.
His RA had been in remission for a number of years treated
with etanercept monotherapy. He was in clinical remission with
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no systemic symptoms. He had positive rheumatoid factor, anti-
citrulinated antibodies and anti-Ro antibodies. ANCA was neg-
ative. Hepatitis B screening had been negative prior to starting
etanercept 5 years earlier.While we did not perform coeliac axis
angiography, PAN, AAV and rheumatoid vasculitis were thought
less likely. There was no role for colour Doppler ultrasound or
positron emission tomography-CT as there was no evidence of
a large vessel vasculitis. Etanercept and other tumour necrosis
factor α inhibitors (TNFα) are known to cause vasculitis, but
no previous case of SOV has been attributed to TNFα in the
literature. Neither carbidopa levodopa nor mirtazapine has been
associated with vasculitis. Our final diagnosis was SOV, which
may or may not have been drug-induced.
The etanercept had been stopped around the time of the
orchidectomy due to surgical risks and subsequent vasculitis
diagnosis. There was careful consideration as to whether it
should be restarted. Considering there have been no previous
documented cases of SOV related to TNFα, he was in remission
on this therapy, and SOV of the testis is treated by the removal
of the affected organ with a low recurrence rate; it was felt that
the drug could be restarted.
DISCUSSION
The Chapel Hill consensus conference defined SOV as ‘Vasculitis
in arteries or veins of any size in a single organ that has no
features that indicate that it is a limited expression of a sys-
temic vasculitis’ [2]. SOV has a better prognosis and requires
less aggressive therapy than systemic vasculitis, but reviewing
the patient for at least 6 months to ensure no progression is
recommended [3].
Testicular vasculitis is rare, having been reported in only
0.003% of surgeries [4] of testicular lesions and presents as a
painful mass in the testis. About 80% of cases are unilateral,
and surgical removal is considered curative; no further systemic
treatment should be required.
Systemic vasculitis is identified by raised inflammatory
markers, constitutional symptoms as well as specific organ
involvement. PAN is the systemic vasculitis most commonly
associated with testicular involvement, but the latter can
be seen in AAV. Behçet’s disease, IgA vasculitis, relapsing
polychondritis and RA can also affect the testis but, in the
case of RA, predominantly as a vasculitis or serositis with
systemic symptoms and active arthritis. Our patient’s RA was in
remission.
Etanercept and other TNFα inhibitors have been known to
cause a cutaneous leucocytoclastic vasculitis and a systemic
vasculitis affecting the kidney or peripheral nerves [5, 6], but not
SOV. It is doubtful that the TNFα was the cause of our patient’s
testicular vasculitis.
With RA and a drug unfamiliar to many physicians, our
patient was treated cautiously. His TNFα inhibitor was withheld,
which adversely affected his rheumatoid disease control. After
a period of ∼6 months following orchidectomy, etanercept was
reintroduced with monitoring for recurrence, and he regained
rheumatoid remission.
In spite of there being no evidence linking etanercept to SOV,
therewas a diagnostic biaswhichmeant that he stayed off a drug
essential for his well-being longer than necessary. It is important
not to assume blame when faced with unfamiliar diagnoses or
drugs but to consider the literature available.
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